恆瑞醫藥(600276.SH):SHR3680片臨牀試驗補充申請獲批
格隆匯6月24日丨恆瑞醫藥(600276.SH)公佈,公司近日收到國家藥監局核准簽發關於SHR3680片的《藥物臨牀試驗補充申請批准通知書》,將於近期開展臨牀試驗。
SHR3680是一種AR受體拮抗劑。目前全球已有比卡魯胺、恩扎盧胺等6個AR拮抗劑上市,在中國有比卡魯胺、恩扎盧胺、阿帕他胺和達羅他胺獲批上市。經查詢Evaluate Pharma數據庫,比卡魯胺2020年度全球銷售額約為2.16億美元,恩扎盧胺2020年度全球銷售額約為43.25億美元,阿帕他胺2020年度全球銷售額約為7.6億美元。截至目前,SHR3680相關研發項目累計已投入研發費用約為2.5183億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.